Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rhythm Pharmaceuticals (RYTM) Debt to Equity (2016 - 2025)

Historic Debt to Equity for Rhythm Pharmaceuticals (RYTM) over the last 5 years, with Q3 2025 value amounting to $0.73.

  • Rhythm Pharmaceuticals' Debt to Equity changed N/A to $0.73 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.73, marking a year-over-year change of. This contributed to the annual value of $5.05 for FY2024, which is 70824.61% up from last year.
  • Latest data reveals that Rhythm Pharmaceuticals reported Debt to Equity of $0.73 as of Q3 2025.
  • Rhythm Pharmaceuticals' Debt to Equity's 5-year high stood at $5.78 during Q1 2025, with a 5-year trough of -$9.22 in Q2 2025.
  • Over the past 3 years, Rhythm Pharmaceuticals' median Debt to Equity value was $0.73 (recorded in 2025), while the average stood at $0.59.
  • Data for Rhythm Pharmaceuticals' Debt to Equity shows a peak YoY increase of 70824.61% (in 2024) and a maximum YoY decrease of 70824.61% (in 2024) over the last 5 years.
  • Rhythm Pharmaceuticals' Debt to Equity (Quarter) stood at $0.63 in 2023, then soared by 708.25% to $5.05 in 2024, then plummeted by 85.51% to $0.73 in 2025.
  • Its Debt to Equity stands at $0.73 for Q3 2025, versus -$9.22 for Q2 2025 and $5.78 for Q1 2025.